Sugi Predict

Sugi Predict / Targets / CALCRL

CALCRL

Calcitonin gene-related peptide type 1 receptor · Q16602 · CALCRL on Sugi Atlas →

35,144 patent compounds predicted against CALCRL, 21,827 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Epimer A Epimer A (SCHEMBL260272) 1.00 20/20
SCHEMBL442897 SCHEMBL442897 1.00 20/20
SCHEMBL828517 SCHEMBL828517 1.00 20/20
SCHEMBL829244 SCHEMBL829244 1.00 20/20
Mk3207 Mk3207 (SCHEMBL992191) 1.00 20/20
SCHEMBL1197392 SCHEMBL1197392 1.00 20/20
SCHEMBL1197959 SCHEMBL1197959 1.00 20/20
SCHEMBL1198235 SCHEMBL1198235 1.00 20/20
Telcagepant Telcagepant (SCHEMBL1198535) 1.00 20/20
SCHEMBL1198570 SCHEMBL1198570 1.00 20/20
SCHEMBL1198651 SCHEMBL1198651 1.00 20/20
SCHEMBL261298 SCHEMBL261298 0.93 20/20
SCHEMBL1198551 SCHEMBL1198551 0.90 20/20
SCHEMBL1198140 SCHEMBL1198140 0.87 20/20
SCHEMBL978979 SCHEMBL978979 0.85 20/20
SCHEMBL828503 SCHEMBL828503 0.85 20/20
SCHEMBL830460 SCHEMBL830460 0.85 20/20
SCHEMBL1071205 SCHEMBL1071205 0.85 20/20
SCHEMBL979196 SCHEMBL979196 0.84 20/20
SCHEMBL261311 SCHEMBL261311 0.84 20/20

Clinical trials — most relevant to CALCRL by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Hypersensitivity to CGRP as a Predictive Biomarker of Migraine Prevention With Erenumab PHASE4UNKNOWN
Novel Combination Therapy for Osteoporosis in Men PHASE4ACTIVE_NOT_RECRUITING
Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic Migraine PHASE4COMPLETED
Decoding Pain Sensitivity in Migraine With Multimodal Brainstem-based Neurosignature PHASE4UNKNOWN
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications PHASE4ACTIVE_NOT_RECRUITING
The Study of Efficacy and Safety of REGPARA Drug in Dialysis Patients Have High Blood Levels of Parathyroid PHASE4COMPLETED
The Nordic Chronic Migraine Trial of CGRP Monoclonal Antibody and Onabotulinumtoxin A Dual Therapy Compared to CGRP mAbs Monotherapy PHASE3RECRUITING
A Study of LY2951742 (Galcanezumab) in Japanese Participants With Migraine PHASE3COMPLETED
A Study on How NNC0174-1213 Works in People With Overweight or Obesity. PHASE1RECRUITING
PTHrP(1-36) IV Dose Escalation Study PHASE1WITHDRAWN
Procalcitonin Increase Identifies Critically Ill Patients at High Risk of Mortality nanCOMPLETED
Clinical Characteristics and Pathophysiology of Post-Traumatic Headache nanCOMPLETED
Longitudinal Analysis of Amylin Levels in Migraine Patients Undergoing an Anti- CGRP/CGRPr Treatment nanNOT_YET_RECRUITING
Evaluation of Microbial and Endocrinological Parameters in Dialysis Patients With Sepsis nanRECRUITING
CGRP Induced Migraine Attacks in Patients With High and Low Genetic Load nanCOMPLETED
Selective Activation of the Adrenomedullin Receptors in Migraine nanNOT_YET_RECRUITING
Potential Osteocatabolic Effect Caused by Anti-CGRP mAbs in Migraine Patients Treated With Anti-CGRP mAbs - an Observational Pilot Project With Prospectively Collected Health Related Data nanACTIVE_NOT_RECRUITING
Amylin and CGRP Head to Head Provocation in Migraine Without Aura Patients nanCOMPLETED
Procalcitonin in Diagnosis of Sepsis in Critically Ill Patient nanUNKNOWN
Parathyroid Hormone (PTH) Homeostasis in Bartter Syndrome nanUNKNOWN
Impact of Clinical, Demographic and Laboratory Variables on Brain Natriuretic Peptide Levels nanWITHDRAWN
Comparison of Treximet & Imitrex as They Affect the Levels of Inflammatory Markers When the Patient is Actively Having a Migraine Headache nanCOMPLETED
Effect of Osteopathic Intervention on Migraine nanNOT_YET_RECRUITING
Monoclonal Antibody Duration of REsponse in MIgraine After Treatment Interruption nanUNKNOWN
Calcitonin for Treating X-linked Hypophosphatemia nanCOMPLETED
The Role of Cytokines and Regulatory T Lymphocytes in Migraine Pathophysiology. nanRECRUITING
Induction of Migraine Attacks With Aura Using Calcitonin Gene-Related Peptide nanRECRUITING
Calcitonin Gene-related Peptide in Familial Hemiplegic Migraine (FHM) and Migraine With Aura (MA) nanCOMPLETED
Assessment of Disease Severity, Progression and Treatment in Infected Patients Presenting to the Emergency Department nanCOMPLETED
Regulation of Vitamin D Receptor (VDR),Calcium Sensing Receptor (CaSR), Cyclin D1,Ki67 and Proliferating Cell Nuclear Antigen (PCNA) in Primary Hyperparathyroidism nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a CALCRL binder may also engage these)

ProteinNameSimilarity
Q63118 — 1.000 Q63118 →
Q9IB86 — 1.000 Q9IB86 →
Q68EK2 — 1.000 Q68EK2 →
Q0P4Y4 — 1.000 Q0P4Y4 →
A6QP74 — 1.000 A6QP74 →
O08893 — 0.998 O08893 →
Q7ZXS8 — 0.997 Q7ZXS8 →
Q9R1W5 — 0.997 Q9R1W5 →
Q8AXU4 — 0.997 Q8AXU4 →
CALCR Calcitonin receptor 0.997 landscape →
VIPR2 Vasoactive intestinal polypeptide receptor 2 0.996 landscape →
Q8WN93 — 0.996 Q8WN93 →
P79222 — 0.995 P79222 →
Q95NQ0 — 0.993 Q95NQ0 →
P35000 — 0.992 P35000 →
P35464 — 0.991 P35464 →
GLP1R Glucagon-like peptide 1 receptor 0.990 landscape →
Q29627 — 0.990 Q29627 →
P30083 — 0.990 P30083 →
P25117 — 0.989 P25117 →
Q95NT6 — 0.989 Q95NT6 →
O35659 — 0.988 O35659 →
Q90308 — 0.988 Q90308 →
P32214 — 0.987 P32214 →
Q9VRN2 — 0.986 Q9VRN2 →
Q60755 — 0.986 Q60755 →
P70205 — 0.986 P70205 →
Q9W0R5 — 0.985 Q9W0R5 →
P41588 — 0.985 P41588 →
Q28992 — 0.985 Q28992 →